Psoriasis Symptoms and Impacts Measure (P-SIM) responses from the BE SURE bimekizumab in moderate to severe plaque psoriasis phase 3 trial

被引：0
|
作者：
Warren, Richard B. [1 ]
Augustin, Matthias [2 ]
Gottlieb, Alice B. [3 ]
Duffin, Kristina Callis [4 ]
Ciaravino, Valerie [5 ]
Cioffi, Christopher [6 ]
Peterson, Luke [6 ]
Blauvelt, Andrew [7 ]
机构：
[1] Univ Manchester, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester NIHR Biomed Res Ctr, Manchester, Lancs, England
[2] Univ Med Ctr Hamburg Eppendorf UKE, Inst Hlth Serv Res Dermatol & Nursing IVDP, Hamburg, Germany
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[5] UCB Pharma, Colombes, France
[6] UCB Pharma, Raleigh, NC USA
[7] Oregon Med Res Ctr, Portland, OR USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27373
引用
收藏
页码：AB138 / AB138
页数：1
相关论文
共 50 条
  • [21] Bimekizumab response maintenance up to 1 year in patients with moderate to severe plaque psoriasis: Pooled results from three phase 3 trials
    Blauvelt, Andrew
    Tada, Yayoi
    Iversen, Lars
    Mrowietz, Ulrich
    Lebwohl, Mark
    Wang, Maggie
    Vanvoorden, Veerle
    Cullen, Eva
    Staelens, Fabienne
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB140 - AB140
  • [22] Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial
    Bissonnette, R.
    Iversen, L.
    Sofen, H.
    Griffiths, C. E. M.
    Foley, P.
    Romiti, R.
    Bachinsky, M.
    Rottinghaus, S. T.
    Tan, H.
    Proulx, J.
    Valdez, H.
    Gupta, P.
    Mallbris, L.
    Wolk, R.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 37 - 37
  • [23] Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
    Gordon, Kenneth B.
    Foley, Peter
    Krueger, James G.
    Pinter, Andreas
    Reich, Kristian
    Vender, Ronald
    Vanvoorden, Veerle
    Madden, Cynthia
    White, Katy
    Cioffi, Christopher
    Blauvelt, Andrew
    LANCET, 2021, 397 (10273): : 475 - 486
  • [24] Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Reply
    Gordon, Kenneth B.
    Colombel, Jean-Frederic
    Hardin, Dana S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (21): : 2102 - 2102
  • [25] Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the openlabel extension period of the BE RADIANT phase 3b trial
    Strober, Bruce
    Paul, Carle
    Blauvelt, Andrew
    Thaci, Diamant
    Elewski, Boni
    White, Katy
    Vanvoorden, Veerle
    Deherder, Delphine
    Staelens, Fabienne
    Eyerich, Kilian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
  • [26] Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials
    Gordon, Kenneth B.
    Langley, Richard G.
    Warren, Richard B.
    Okubo, Yukari
    Rosmarin, David
    Lebwohl, Mark
    Peterson, Luke
    Madden, Cynthia
    de Cuyper, Dirk
    Davies, Owen
    Thaci, Diamant
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (04) : 477 - 485
  • [27] Efficacy and Safety of Bimekizumab vs. Adalimumab in moderate to severe Plaque Psoriasis: Results of a multicenter, randomized, double-blind Phase III Study (BE SURE Study)
    Warren, R. B.
    Blauvelt, A.
    Bagel, J.
    Papp, K. A.
    Yamauchi, P.
    Armstrong, A.
    Langley, R.
    Vanvoorden, V.
    Peterson, L.
    De Cuyper, D.
    Cross, N.
    Reich, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 59 - 59
  • [28] Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial
    Strober, Bruce
    Tada, Yayoi
    Mrowietz, Ulrich
    Lebwohl, Mark
    Foley, Peter
    Langley, Richard G.
    Warren, Richard B.
    Wang, Maggie
    Vanvoorden, Veerle
    Szilagyi, Balint
    Ciaravino, Valerie
    Paul, Carle
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (06) : 749 - 759
  • [29] DEFINING SEVERITY CATEGORY THRESHOLDS TO GUIDE PSORIASIS SYMPTOMS AND IMPACTS MEASURE SCORE INTERPRETATION USING POOLED DATA FROM THREE PHASE 3 TRIALS IN PLAQUE PSORIASIS
    Augustin, M.
    Ab, Gottlieb
    Warham, R.
    Lambert, J.
    Hoepken, B.
    Warren, R. B.
    VALUE IN HEALTH, 2023, 26 (12) : S402 - S403
  • [30] Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: Results from the SustaIMM phase 2/3 trial
    Ohtsuki, Mamitaro
    Fujita, Hideki
    Watanabe, Mitsunori
    Suzaki, Keiko
    Flack, Mary
    Huang, Xin
    Kitamura, Susumu
    Valdes, Joaquin
    Igarashi, Atsuyuki
    JOURNAL OF DERMATOLOGY, 2019, 46 (08): : 686 - 694
12345